Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial

Selim Corbacioglu, Simone Cesaro, Maura Faraci, Dominique Valteau-Couanet, Bernd Gruhn, Attilio Rovelli, Jaap J. Boelens, Annette Hewitt, Johanna Schrum, Ansgar S. Schulz, Ingo Müller, Jerry Stein, Robert Wynn, Johann Greil, Karl Walter Sykora, Susanne Matthes-Martin, Monika Führer, Anne O'Meara, Jacek Toporski, Petr SedlacekPaul G. Schlegel, Karoline Ehlert, Anders Fasth, Jacek Winiarski, Johan Arvidson, Christine Mauz-Körholz, Hulya Ozsahin, Andre Schrauder, Peter Bader, Joseph Massaro, Ralph D'Agostino, Margaret Hoyle, Massimo Iacobelli, Klaus Michael Debatin, Christina Peters, Giorgio Dini

Research output: Contribution to journalArticlepeer-review


Background Hepatic veno-occlusive disease is a leading cause of morbidity and mortality after haemopoietic stem-cell transplantation (HSCT). We aimed to assess whether defi brotide can reduce the incidence of veno-occlusive disease in this setting. Methods In our phase 3 open-label, randomised controlled trial, we enrolled patients at 28 European university hospitals or academic medical centres. Eligible patients were younger than 18 years, had undergone myeloablative conditioning before allogeneic or autologous HSCT, and had one or more risk factor for veno-occlusive disease based on modifi ed Seattle criteria. We centrally assigned eligible participants on the basis of a computer-generated randomisation sequence (1:1), stratifi ed by centre and presence of osteopetrosis, to receive intravenous defi brotide prophylaxis (treatment group) or not (control group). The primary endpoint was incidence of veno-occlusive disease by 30 days after HSCT, adjudicated by a masked, independent review committee, in eligible patients who consented to randomisation (intention-to-treat popu lation), and was assessed with a competing risk approach. Patients in either group who developed veno-occlusive disease received defi brotide for treatment. We assessed adverse events to 180 days after HSCT in all patients who received allocated prophylaxis. This trial is registered with, number NCT00272948. Findings Between Jan 25, 2006, and Jan 29, 2009, we enrolled 356 eligible patients to the intention-to-treat population. 22 (12%) of 180 patients randomly allocated to the defi brotide group had veno-occlusive disease by 30 days after HSCT compared with 35 (20%) of 176 controls (risk diff erence-7.7%, 95% CI-15.3 to-0.1; Z test for competing risk analysis p=0.0488; log-rank test p=0.0507). 154 (87%) of 177 patients in the defi brotide group had adverse events by day 180 compared with 155 (88%) of 176 controls. Interpretation Defi brotide prophylaxis seems to reduce incidence of veno-occlusive disease and is well tolerated. Thus, such prophylaxis could present a useful clinical option for this serious complication of HSCT. Funding Gentium SpA, European Group for Blood and Marrow Transplantation.

Original languageEnglish
Pages (from-to)1301-1309
Number of pages9
JournalThe Lancet
Issue number9823
StatePublished - Apr 2012
Externally publishedYes


Dive into the research topics of 'Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial'. Together they form a unique fingerprint.

Cite this